2024 Virtual Grand Rounds
2024 Virtual Grand Rounds Session 17: December 4, 2024 - JAKing Up Care in Alopecia Areata: Using JAK Inhibitors in Challenging Case Scenarios
About
Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:
Wednesday, December 4, 2024
8 PM ET / 5 PM PT
JAKing Up Care in Alopecia Areata: Using JAK Inhibitors in Challenging Case Scenarios
This activity is supported by educational grants from Lilly USA, LLC and Sun Pharmaceutical Industries Ltd.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
December 5, 2024
December 5, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Describe the latest clinical evidence for the efficacy and safety of oral JAK inhibitors in the management of alopecia areata (AA)
Identify appropriate patients with AA for oral JAK inhibitors based on AA disease severity
Select appropriate dose adjustment strategies to optimize treatment of AA with oral JAK inhibitors
Review shared decision-making approaches to promote patient-centered care with oral JAK inhibitors
Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Carolyn Goh, MD
Associate Clinical Professor of Medicine-Dermatology
UCLA David Geffen School of Medicine
Los Angeles, CA
Arash Mostaghimi, MD, MPH
Vice Chair, Clinical Trials and Innovation
Brigham and Women's Hospital
Director, Dermatology Inpatient Service
Co-Director, Complex Medical Dermatology Fellowship Program
Associate Professor, Harvard Medical School
Boston, MA
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Advisory Board/Consultant: AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Takeda, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Regeneron, Pfizer
Grant/Research Support: AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Takeda, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Regeneron, and Pfizer
Speakers’ Bureau or Honoraria: Pfizer, Inc.
Other Relationships: Royalty: BMJ BestPractices
Advisory Board/Consultant: hims and hers, AbbVie, Sun Pharma, Pfizer, Digital Diagnostics, Lilly, Equillium, ASLAN
Other Relationships: Boehringer Ingelheim, Figure 1, Dermatheory, Olaplex, Legacy Healthcare, Pelage
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.